New mesh may reduce infections in complex hernia surgery

NCT ID NCT01594450

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether using a biological mesh (made from human or animal tissue) during surgery for infected ventral hernias leads to fewer wound problems than standard wound care alone. About 110 adults with infected hernias were randomly assigned to receive either the mesh or standard treatment. Researchers tracked infections, hernia recurrence, pain, and quality of life for up to three years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
biological mesh (acellular dermal matrix)
What this could lead to
If successful, using a biological mesh could lower infection and hernia recurrence rates after surgery for infected ventral hernias.
What could go wrong
This is a completed Phase 3 trial with 110 participants, so results are available but may not apply to all hernia types. Biological meshes are expensive and may not outperform standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENTRAL HERNIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hernia, Ventral

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Claude Huriez Hospital, University hospital

    Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.